These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11597477)

  • 1. Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists.
    Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Sanagi M; Orita M; Nakahara H; Shimaya J; Tsukamoto S; Tanaka A; Yanagisawa I
    Bioorg Med Chem; 2001 Nov; 9(11):2955-68. PubMed ID: 11597477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethenesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists.
    Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Tanaka A; Tsukamoto S; Yanagisawa I
    Chem Pharm Bull (Tokyo); 2001 May; 49(5):606-12. PubMed ID: 11383615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships in a series of ethenesulfonamide derivatives, a novel class of endothelin receptor antagonists.
    Harada H; Kazami J; Watanuki S; Tsuzuki R; Sudoh K; Fujimori A; Tokunaga T; Tanaka A; Tsukamoto S; Yanagisawa I
    Chem Pharm Bull (Tokyo); 2001 Dec; 49(12):1593-603. PubMed ID: 11767080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of potent and orally active sulfonamide ETB selective antagonists.
    Kanda Y; Kawanishi Y; Oda K; Sakata T; Mihara SI; Asakura K; Kanemasa T; Ninomiya M; Fujimoto M; Konoike T
    Bioorg Med Chem; 2001 Apr; 9(4):897-907. PubMed ID: 11354672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist.
    Yuyama H; Sanagi M; Koakutsu A; Mori M; Fujimori A; Harada H; Sudoh K; Miyata K
    Eur J Pharmacol; 2003 Sep; 478(1):61-71. PubMed ID: 14555186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308).
    Murugesan N; Gu Z; Stein PD; Bisaha S; Spergel S; Girotra R; Lee VG; Lloyd J; Misra RN; Schmidt J; Mathur A; Stratton L; Kelly YF; Bird E; Waldron T; Liu EC; Zhang R; Lee H; Serafino R; Abboa-Offei B; Mathers P; Giancarli M; Seymour AA; Webb ML; Hunt JT
    J Med Chem; 1998 Dec; 41(26):5198-218. PubMed ID: 9857090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
    Morimoto H; Shimadzu H; Kushiyama E; Kawanishi H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
    J Med Chem; 2001 Oct; 44(21):3355-68. PubMed ID: 11585441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
    Sudoh K; Yuyama H; Noguchi Y; Fujimori A; Ukai M; Ohtake A; Sato S; Sasamata M; Miyata K
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S390-3. PubMed ID: 15838329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist.
    Yuyama H; Noguchi Y; Fujimori A; Ukai M; Fujiyasu N; Ohtake A; Sato S; Sudoh K; Sasamata M; Miyata K
    Eur J Pharmacol; 2004 Sep; 498(1-3):171-7. PubMed ID: 15363992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor.
    Wu-Wong JR; Dixon DB; Chiou WJ; Dayton BD; Novosad EI; Adler AL; Wessale JL; Calzadilla SV; Hernandez L; Marsh KC; Liu G; Szczepankiewicz B; von Geldern TW; Opgenorth TJ
    Eur J Pharmacol; 1999 Feb; 366(2-3):189-201. PubMed ID: 10082200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
    Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists.
    Riechers H; Albrecht HP; Amberg W; Baumann E; Bernard H; Böhm HJ; Klinge D; Kling A; Müller S; Raschack M; Unger L; Walker N; Wernet W
    J Med Chem; 1996 May; 39(11):2123-8. PubMed ID: 8667356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist.
    Wu C; Chan MF; Stavros F; Raju B; Okun I; Mong S; Keller KM; Brock T; Kogan TP; Dixon RA
    J Med Chem; 1997 May; 40(11):1690-7. PubMed ID: 9171878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
    Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
    J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bis-sulfonamides as endothelin receptor antagonists.
    Boss C; Bolli MH; Weller T; Fischli W; Clozel M
    Bioorg Med Chem Lett; 2003 Mar; 13(5):951-4. PubMed ID: 12617928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and selective ET-A antagonists. 2. Discovery and evaluation of potent and water soluble N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives.
    Morimoto H; Ohashi N; Shimadzu H; Kushiyama E; Kawanishi H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
    J Med Chem; 2001 Oct; 44(21):3369-77. PubMed ID: 11585442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and synthesis of a potent sulfonamide ET(B) selective antagonist.
    Kanda Y; Takahashi T; Araki Y; Konoike T; Mihara S; Fujimoto M
    Bioorg Med Chem Lett; 2000 Aug; 10(16):1875-8. PubMed ID: 10969989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity.
    Cai J; Liu L; Hong KH; Wang P; Li L; Cao M; Sun C; Wu X; Zong X; Chen J; Ji M
    Bioorg Med Chem; 2015 Feb; 23(4):657-67. PubMed ID: 25614116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of PABSA, an orally active and highly potent endothelin-receptor antagonist.
    Iwasaki T; Mihara S; Shimamura T; Kawakami M; Hayasaki-Kajiwara Y; Naya N; Fujimoto M; Nakajima M
    J Cardiovasc Pharmacol; 1999 Jul; 34(1):139-47. PubMed ID: 10413080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modifications and structure-activity relationships at the 2-position of 4-sulfonamidopyrimidine derivatives as potent endothelin antagonists.
    Morimoto H; Shimadzu H; Hosaka T; Kawase Y; Yasuda K; Kikkawa K; Yamauchi-Kohno R; Yamada K
    Bioorg Med Chem Lett; 2002 Jan; 12(1):81-4. PubMed ID: 11738578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.